Shockwave Therapy for Erectile Dysfunction

What Is Erectile Dysfunction?

Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects an estimated 30 million men in the United States, with prevalence increasing with age — roughly 40% of men at age 40 experience some degree of ED, rising to approximately 70% by age 70.

While ED is often discussed as a single condition, it has multiple underlying causes. Vasculogenic ED — caused by impaired blood flow to the penile tissue — is the most common type, accounting for the majority of cases. This is often linked to cardiovascular risk factors including diabetes, hypertension, high cholesterol, and smoking. Other causes include neurological conditions, hormonal imbalances, medication side effects, psychological factors, or a combination of these.

Current first-line treatments include PDE5 inhibitors (phosphodiesterase type 5 inhibitors) like sildenafil and tadalafil, lifestyle modifications, and psychological counseling when appropriate. For patients who don’t respond to medication, options include penile injections, vacuum erection devices, and surgical implants.

Low-intensity extracorporeal shockwave therapy (Li-ESWT) has emerged as an investigational treatment that aims to address the vascular root cause of ED rather than treating symptoms on a per-use basis. It is important to understand that this treatment is still being studied, and its evidence base — while promising — is not yet as robust as established therapies.

How Shockwave Therapy Works for Erectile Dysfunction

The shockwave therapy used for ED is fundamentally different from the high-energy shockwave therapy used for musculoskeletal conditions like plantar fasciitis or tendinopathy. This distinction matters.

Low-intensity extracorporeal shockwave therapy (Li-ESWT) uses acoustic energy at much lower energy flux densities — typically 0.09 to 0.25 mJ/mm2 — compared to the 0.2 to 0.6+ mJ/mm2 used for orthopedic applications. The goal is not to break down tissue or stimulate tendon repair, but rather to trigger neovascularization — the formation of new, small blood vessels in the penile tissue.

The proposed mechanism works as follows: the low-intensity acoustic waves create mild mechanical stress at the cellular level in the penile vasculature. This controlled stimulus activates a cascade of biological signals, including the release of vascular endothelial growth factor (VEGF) and other angiogenic (blood-vessel-forming) factors. Over time, new capillaries develop, potentially improving blood flow to the corpus cavernosum — the spongy erectile tissue that fills with blood during an erection.

Additionally, Li-ESWT may recruit endothelial progenitor cells (stem cells that form the lining of blood vessels) and activate nitric oxide pathways, which play a central role in the erection process.

The key distinction from medication: PDE5 inhibitors work on demand by temporarily enhancing the biochemical pathway that produces an erection, but they do not change the underlying vascular condition. Li-ESWT, in theory, aims to restore vascular function itself — a disease-modifying approach rather than a symptomatic one. Whether it achieves this consistently in practice is what the research is still working to establish.

FDA status: Li-ESWT is NOT FDA-cleared or approved for the treatment of erectile dysfunction. Its use for ED is considered investigational in the United States. This must be clearly understood by any patient considering the treatment. Some shockwave devices have FDA clearances for other conditions, but those clearances do not extend to ED. Any marketing that implies FDA approval for ED is misleading.

What the Research Says

The evidence for Li-ESWT in ED is promising but mixed, and it’s important to present it honestly. Here’s what the key studies show:

Vardi et al. (2012), published in European Urology, conducted one of the first randomized, double-blind, sham-controlled trials of Li-ESWT for ED. The study included 60 men with vasculogenic ED who responded to PDE5 inhibitors. The treatment group received Li-ESWT twice weekly for 3 weeks, repeated after a 3-week break. At one month post-treatment, the ESWT group showed a statistically significant improvement in the International Index of Erectile Function (IIEF) score (+6.7 points) compared to the sham group (+3.0 points). This was an important proof-of-concept study, but it was small and had a relatively short follow-up period.

Lu et al. (2017) published a meta-analysis in European Urology that pooled data from 7 randomized controlled trials involving 602 patients. The analysis found that Li-ESWT produced statistically significant improvements in IIEF scores compared to sham treatment. However, the authors noted substantial heterogeneity between studies — meaning the protocols, patient populations, and outcomes varied considerably — and called for standardized treatment protocols and larger trials.

Clavijo et al. (2017), also in the Journal of Sexual Medicine, published a systematic review of 14 studies and concluded that while Li-ESWT showed short-term improvements in erectile function scores and penile hemodynamics, the overall quality of evidence was low to moderate. Many studies lacked adequate blinding, had small sample sizes, or used inconsistent treatment protocols.

The European Association of Urology (EAU) has included Li-ESWT in its guidelines as an option for vasculogenic ED, with a conditional recommendation. The American Urological Association (AUA) has been more conservative, noting that the evidence is not yet sufficient for a definitive recommendation.

A 2019 study by Kitrey et al. followed patients for two years after Li-ESWT and found that approximately 53% of initial responders maintained improvement at the 2-year mark, suggesting the effects may diminish over time for some patients.

An honest assessment

The research trend is positive. Li-ESWT appears to provide meaningful improvement in erectile function for a subset of patients, particularly those with mild to moderate vasculogenic ED. However, several limitations exist:

• Most studies are small (under 100 patients).
• Treatment protocols vary widely — different devices, energy levels, number of sessions, and treatment intervals make it hard to identify the optimal approach.
• Long-term data beyond 1 to 2 years is scarce.
• The response is not universal — not all patients improve, and predictors of who will respond best are still being defined.
• Publication bias may favor positive results.

A note about “wave therapy” marketing

The growth of men’s health clinics offering “wave therapy,” “acoustic wave therapy,” or similarly branded treatments has outpaced the clinical evidence. Some of these clinics use aggressive marketing, guarantee outcomes, sell high-priced treatment packages ($3,000 to $12,000+), and overstate what the research supports. This does a disservice to patients and to the legitimate scientific investigation of Li-ESWT.

If you are considering this treatment, seek out providers who are transparent about the investigational nature of Li-ESWT, discuss realistic expectations, and don’t rely on guarantees or high-pressure sales.

What to Expect During Treatment

A Li-ESWT session for ED is a non-invasive outpatient procedure that typically takes 15 to 20 minutes:

Before treatment: A qualified provider should conduct a comprehensive evaluation, including medical history, cardiovascular risk assessment, and potentially blood work (hormone levels, metabolic panel). Some providers use penile duplex ultrasound to assess blood flow before treatment. You should be informed that this is an investigational, off-label use of the technology.

During the session: You will lie on an examination table. The provider applies coupling gel to the penile shaft and surrounding area. A handheld applicator is placed against the skin, and low-intensity acoustic pulses are delivered to multiple points along the penile shaft and at the crura (the base of the erectile tissue near the perineum).

The pulses feel like a mild tapping or tingling. Most patients report minimal to no pain — this is a distinctly different experience from high-energy shockwave therapy used for musculoskeletal conditions. Typical protocols deliver 3,000 to 5,000 pulses per session at low energy settings.

No anesthesia or numbing is required. There is no downtime.

After treatment: You can resume all normal activities immediately, including sexual activity. There are no restrictions following the procedure. Some patients report a mild warming sensation or slight tingling in the treatment area for a few hours afterward.

Number of Sessions & Recovery Timeline

Treatment protocols vary between providers and studies, but common approaches include:

• 6 to 12 sessions total
• Delivered twice per week or once per week
• Some protocols use a split approach: 6 sessions over 3 weeks, a 3-week rest period, then 6 more sessions over 3 weeks (the “Vardi protocol”)
• Other protocols deliver sessions once weekly for 6 to 12 consecutive weeks

There is no universally agreed-upon optimal protocol, which is one of the current limitations in the field. When evaluating a provider, it is reasonable to ask which protocol they follow and why.

Timeline for potential results:

• During treatment: Some patients report subjective improvement after the first few sessions. Changes at this stage may be partly related to placebo effect, which is significant in ED studies (sham groups often improve by 30% or more).
• 4-8 weeks after completing treatment: This is the window where meaningful changes in erectile function are most commonly reported. The biological processes of neovascularization take time.
• 3-6 months: Peak improvement is typically observed during this period in clinical studies.
• Beyond 6 months: Durability of response varies. Some patients maintain improvement; others experience partial regression.

There is no significant recovery from individual sessions. Li-ESWT is painless to mildly uncomfortable, with no tissue damage, bruising, or activity restrictions.

Cost & Insurance Coverage

Li-ESWT for ED typically costs $400 to $800 per session, with complete treatment courses ranging from $2,400 to $9,600 depending on the number of sessions and provider pricing.

Insurance does not cover shockwave therapy for ED. Because it is not FDA-approved for this indication, no major insurance carrier or Medicare reimburses the procedure. This is an entirely out-of-pocket cost.

Some important cost considerations:

• Beware of high-pressure package pricing. Some clinics sell treatment packages ranging from $3,000 to $12,000 or more, often with pressure to commit during the first visit. A reputable provider will give you time to consider treatment without urgency tactics.
• Ask what’s included. Does the per-session cost include the initial evaluation? Follow-up assessments? What happens if you don’t respond — is there a retreatment policy?
• Compare the ongoing cost of alternatives. PDE5 inhibitors can cost $30 to $70 per dose (or $10 to $15 for generics). Over time, the cumulative cost of on-demand medication may approach or exceed a course of Li-ESWT — though medication has a more established evidence base.
• Financing and payment plans are offered by some clinics. Evaluate these objectively and avoid committing to large sums under pressure.

The cost-effectiveness question is genuine but unresolved. If Li-ESWT produces durable improvement, the upfront cost may represent good value compared to years of medication. If the effects are temporary and retreatment is needed, the economics change.

Who Is a Good Candidate?

Based on the current evidence, the patients most likely to benefit from Li-ESWT for ED include:

Potentially good candidates:

• Men with mild to moderate vasculogenic ED — the evidence is strongest in this group
• Men who respond to PDE5 inhibitors but want to explore reducing medication dependence (several studies enrolled PDE5-responsive patients)
• Men with ED related to cardiovascular risk factors (diabetes, hypertension, high cholesterol) where impaired blood flow is the primary mechanism
• Men who prefer to try a non-pharmacological, non-invasive approach before escalating to injections or surgical options

Less likely to benefit (based on current evidence):

• Men with severe ED that does not respond to PDE5 inhibitors — evidence in this population is weaker and more inconsistent
• ED caused primarily by neurological conditions (e.g., post-prostatectomy nerve damage, spinal cord injury) — Li-ESWT targets vascular mechanisms and would not address nerve-related causes
• ED that is primarily psychological in origin — while some improvement may occur via placebo or general well-being effects, this is not the intended target of the therapy
• Men with Peyronie’s disease — while ESWT has been studied for Peyronie’s, it is a different condition requiring different evaluation (some studies suggest it may help with pain but not curvature)

Shockwave therapy is contraindicated for:

• Men on anticoagulant therapy or with bleeding disorders
• Active urinary tract or genital infections
• Penile implants in the treatment area
• Active malignancy in the pelvic region

Before pursuing Li-ESWT for ED, consider:

1. Have you had a thorough evaluation by a urologist to determine the cause of your ED?
2. Have you tried first-line treatments (lifestyle changes, PDE5 inhibitors)?
3. Has your provider clearly communicated that this is an investigational treatment?
4. Are you comfortable with the out-of-pocket cost and the possibility that it may not work?
5. Is the provider discussing realistic expectations, or are they guaranteeing results?

A qualified provider will address all of these points before recommending treatment.

References

1. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. Eur Urol. 2012;61(5):1126-1133.
2. Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity extracorporeal shock wave treatment improves erectile function: A systematic review and meta-analysis. Eur Urol. 2017;71(2):223-233.
3. Clavijo RI, Navon JD, Menachem A, Trotter PT, et al. Low-intensity extracorporeal shockwave therapy for erectile dysfunction: A systematic review and meta-analysis of clinical trials. J Sex Med. 2017;14(1):27-35.
4. Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwi O, Vardi Y. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: A double-blind, sham controlled study. J Urol. 2016;195(5):1550-1555.
5. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health. 2023. Available at: https://uroweb.org/guidelines/sexual-and-reproductive-health
6. Kitrey ND, Vardi Y, Appel B, et al. Low intensity shock wave treatment for erectile dysfunction — how long does the effect last? J Urol. 2019;201(Supplement 4):e665.